232 related articles for article (PubMed ID: 32616554)
21. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Chin SM; Kimberlin CR; Roe-Zurz Z; Zhang P; Xu A; Liao-Chan S; Sen D; Nager AR; Oakdale NS; Brown C; Wang F; Yang Y; Lindquist K; Yeung YA; Salek-Ardakani S; Chaparro-Riggers J
Nat Commun; 2018 Nov; 9(1):4679. PubMed ID: 30410017
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of cancer with 4-1BB.
Vinay DS; Kwon BS
Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
[TBL] [Abstract][Full Text] [Related]
23. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
24. Tumor expression of 4-1BB ligand sustains tumor lytic T cells.
Zhang H; Merchant MS; Chua KS; Khanna C; Helman LJ; Telford B; Ward Y; Summers J; Toretsky J; Thomas EK; June CH; Mackall CL
Cancer Biol Ther; 2003; 2(5):579-86. PubMed ID: 14614331
[TBL] [Abstract][Full Text] [Related]
25. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.
Schabowsky RH; Elpek KG; Madireddi S; Sharma RK; Yolcu ES; Bandura-Morgan L; Miller R; MacLeod KJ; Mittler RS; Shirwan H
Vaccine; 2009 Dec; 28(2):512-22. PubMed ID: 19836479
[TBL] [Abstract][Full Text] [Related]
26. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
Zhao Y; Croft M
Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
[TBL] [Abstract][Full Text] [Related]
27. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
28. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy targeting 4-1BB and its ligand.
Vinay DS; Kwon BS
Int J Hematol; 2006 Jan; 83(1):23-8. PubMed ID: 16443548
[TBL] [Abstract][Full Text] [Related]
30. Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell.
Wu C; Guo H; Wang Y; Gao Y; Zhu Z; Du Z
Cell Immunol; 2011; 271(1):118-23. PubMed ID: 21745658
[TBL] [Abstract][Full Text] [Related]
31. HBcAg-induced upregulated 4-1BB ligand on B cells contributes to B-cell hyperactivation during chronic hepatitis B infection.
Liu Y; Wang G; Chen Y; Huang R; Tian C; Li Y; Zhao XA; Wu C
J Med Virol; 2019 May; 91(5):781-790. PubMed ID: 30552705
[TBL] [Abstract][Full Text] [Related]
32. The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson MH; Fritzell S; Miller R; Werchau D; Van Citters D; Nilsson A; Misher L; Ljung L; Bader R; Deronic A; Chunyk AG; Schultz L; Varas LA; Rose N; Håkansson M; Gross J; Furebring C; Pavlik P; Sundstedt A; Veitonmäki N; Ramos HJ; Säll A; Dahlman A; Bienvenue D; von Schantz L; McMahan CJ; Askmyr M; Hernandez-Hoyos G; Ellmark P
Mol Cancer Ther; 2023 Jan; 22(1):89-101. PubMed ID: 36343381
[TBL] [Abstract][Full Text] [Related]
33. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
34. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
[TBL] [Abstract][Full Text] [Related]
35. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.
Daniel-Meshulam I; Horovitz-Fried M; Cohen CJ
Int J Cancer; 2013 Dec; 133(12):2903-13. PubMed ID: 23754772
[TBL] [Abstract][Full Text] [Related]
36. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.
Futagawa T; Akiba H; Kodama T; Takeda K; Hosoda Y; Yagita H; Okumura K
Int Immunol; 2002 Mar; 14(3):275-86. PubMed ID: 11867564
[TBL] [Abstract][Full Text] [Related]
37. 4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T.
Shen X; Zhang R; Nie X; Yang Y; Hua Y; Lü P
Cancer Biother Radiopharm; 2023 Sep; 38(7):431-444. PubMed ID: 37433196
[TBL] [Abstract][Full Text] [Related]
38. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
40. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
